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Nature MediciNe landscape along the 23 generations of the airways in human lung is expected to differ both in terms of relative frequencies of cell types and their molecular phenotype 1 . We used 10x Genomics Chromium droplet single-cell RNA sequencing (scRNA-seq) to profile a total of 36,931 single cells from upper and lower airways and lung parenchyma (Fig. 1a, b and Supplementary Table 1) . We profiled nasal brushes, bronchial brushes, and airway wall biopsies (third to sixth generation) from healthy volunteers. For parenchyma (small respiratory airways and alveoli), we obtained lung tissue from deceased transplant donors.
Our analysis reveals a diversity of epithelial, endothelial, stromal, and immune cells, with approximately 21 coarse-grained cell types in total (Figs. 1 and 2 and Extended Data Fig. 1 ), that can be explored in a user-friendly web portal (www.lungcellatlas.org). We further confirmed our observations by comparing our dataset with parenchymal lung tissue from resection material analyzed on a bespoke Drop-seq-like microfluidics platform 2 (Extended Data Fig. 2 ). We observed extensive overlap in cell-type identities (Extended Data Fig. 2 ). In our analysis below, we first concentrate on epithelial cells ( Fig. 1 ) and then focus on the stromal and immune compartments ( Fig. 2) .
In the epithelial lineage, we identified at least ten cell types across the upper and lower airways and lung parenchyma (Fig. 1c and Extended Data Fig. 1 ). We detected multiple basal, club, ciliated, and goblet cell states, as well as type 1 and type 2 alveolar cells, and the recently described ionocyte 3, 4 (Fig. 1d and Extended Data Fig. 3 ). We did not identify specific clusters of tuft cells or neuroendocrine cells. Supervised analysis using neuroendocrine (CHGA, ASCL1, INSM1, HOXB5) and tuft (DCLK1, ASCL2) 3 cell marker genes identified a small number of cells with neuroendocrine-like features present only in lower airways (Extended Data Fig. 4 ). Tuft cell marker genes did not identify a unique cell population.
We identified two discrete cell states in each of basal, goblet, and ciliated epithelial cells. Basal cells were present in upper and lower airways, although at relatively low frequency in upper airways (Fig. 1e) . The two basal cell states corresponded to differentiation stages, with the less-mature basal 1 cell state expressing higher levels of TP63 and NPPC compared with more-mature basal 2 cells ( Fig. 1f and Extended Data Fig. 1 ), which were more abundant in bronchial brushes, suggesting a more apical localization (Fig. 1d,e) . Goblet 1 and 2 cells were both characterized by high expression of CEACAM5, S100A4 and MUC5AC, and lack of MUC5B (Fig. 1f and Extended Data Figs. 1 and 4) . Goblet 1 cells specifically express KRT4 and CD36 (Fig. 1g and Extended Data Fig. 4) . Genes involved in recruitment of neutrophils, monocytes, dendritic cells, and T cells 5 , such as IDO1, NOS2, IL19, CSF3 (granulocyte-colony stimulating factor), and CXCL10 are expressed at high levels in goblet 2 cells (Fig. 1f ,g and Extended Data Fig. 4 ). Both goblet cell states are present in upper airway epithelium. In contrast, only the goblet 2 cell state was present in lower airways, albeit at low abundance (Fig. 1e) .
Ciliated cells were also zonated in terms of their presence across macro-anatomical locations, with a discrete ciliated cell state more abundant in upper airways (ciliated 2) compared with lower airways and lung parenchyma. Nasal epithelial ciliated 2 cells express proinflammatory genes, such as CCL20, and higher levels of metabolic (ATP12A and COX7A1) and vesicle transport (AP2B1 and SYT5 6 ) genes compared with the ciliated 1 cells (Extended Data Fig. 4 ). In contrast, the ciliated 1 cells from lower airways specifically expressed genes involved in cytoprotection ( PROS1 7 ) and fluid reabsorption ( FXYD1 8 ) (Fig. 1h and Extended Data Fig. 4) . We detected a location-specific transcriptional signature specific for the upper airways in both ciliated and goblet cells (Extended Data Fig. 4b ).
Next, we assessed the contribution of specific epithelial cell types to Mendelian disease. Cell type-specific expression patterns of genes associated with Mendelian disorders (based on the Online Mendelian Inheritance in Man (OMIM) database) confirmed ionocytes as particularly high expressors of the CFTR gene, mutated in cystic fibrosis (Fig. 1i and Supplementary Table 2) . These cells also express SCNN1B, mutations of which can cause bronchiectasis, another feature of cystic fibrosis, suggesting a pathological role for ionocytes in both bronchiectasis and cystic fibrosis. In addition, expression of SERPINA1 (Fig. 1i ) was found to be enriched in type 2 alveolar epithelial cells, underscoring their role in alpha-1-antitrypsin deficiency 9 .
Differential anatomical distribution of the stromal and immune components in the human respiratory tree. Next, we analyzed the single-cell transcriptomes of immune and stromal cells from the upper airways, lower airways, and the lung parenchyma (Fig. 2a) . We identified immune clusters of myeloid (macrophages, neutrophils, dendritic cells, and mast cells) and lymphoid cells (T and natural killer cells, B cells; Fig. 2b and Extended Data Fig. 5) . Immune and stromal cell numbers and composition varied greatly across different anatomical regions (Fig. 2a,c) . Nasal brushes contained only a small number of immune cells, with the large majority being dendritic cells. In the lower airways, the fraction of inflammatory cells was much larger and relatively enriched for macrophages (Fig. 2c and Extended Data Fig. 5) , which was directly confirmed by cell composition comparison of upper versus lower airway brushes obtained from the same donor (Extended Data Fig. 5e ). The stromal component of the parenchyma region was dominated by vascular endothelial cells with a small number of fibroblasts, while the upper airways had a richer stromal compartment, with fibroblasts, myofibroblasts, smooth muscle, vascular, and lymphatic endothelial cells (Fig. 2d) .
Macrophage transcriptional phenotypes showed large donor variation (Extended Data Fig. 5 ), but they all shared high expression of MARCO, CCL18, and genes involved in apolipoprotein metabolism (APOC1 and APOE) (Fig. 2e and Extended Data Fig. 5) . Lung neutrophils express high levels of the granulocyte markers S100A8, S100A12
10
, and LILRA5, a receptor poorly characterized in the lungs that has been shown to have a proinflammatory function in synovial fluid macrophages 11 (Fig. 2e and Extended Data Fig. 5) . Dendritic cells were mostly myeloid, with high expression of CD1E, CD1C, and CLEC10A (Fig. 2e and Extended Data Fig. 5 ) and of FCER1A (IgE receptor) and CCL17, which have a key role in inflammatory conditions such as asthma 12 .
In the scRNA-seq datasets, we could not distinguish T cells and natural killer cells from each other (Fig. 2b) . The B cells in our dataset were mostly plasma cells, expressing high levels of JCHAIN. IgM + (IGHM) B cells were enriched in the bronchial brushes and in the lung parenchyma, while IgG3 + (IGHG3) B cells were enriched in airway biopsy samples and were virtually absent from the bronchial brushes, suggesting a micro-anatomical segregation of B cell subsets (Extended Data Fig. 5f ). The immune and stromal lung components also displayed cell type-specific expression patterns of genes associated with Mendelian disorders. However, in contrast to epithelial cell associated syndromes, syndromes associated with immune and stromal cells were largely systemic in nature (with lung involvement 13 ) (Fig. 2f ).
Molecular features of mucous cell metaplasia in asthma.
Asthma is a complex and heterogeneous disease 14 , where epithelial 15, 16 , stromal 17 , and immune cells 18, 19 contribute to a spectrum of clinical phenotypes. We analyzed bronchial biopsies from six volunteers with chronic, childhood-onset asthma (Fig. 3a and Supplementary  Table 3 ) and compared them with bronchoscopy samples obtained from healthy sex-and age-matched volunteers (Supplementary Table 3 ). The Global Initiative for Asthma (GINA) score at time of recruitment indicated patients had either mild or moderate asthma (Supplementary Table 3 Goblet 1  Goblet 2   SCGB3A2  AGER  CAV1  RNASE1  HOPX  CTSE  PGC  SFTPD  SFTPC  SFTA2  SFTPA2  NAPSA  SFTPA1  SFTPB  SCG2  RARRES2  ATP6V1G3  IGF1  CLCNKB  STAP1  ASCL3  FOXI1  TFCP2L1  CEACAM5  PSCA  S100A4  ASRGL1  LYNX1  LYPD2  CXCL10  IL-19  S100A8  SLC26A4  NOS2  PI3  IDO1  CXCL6  TFF3  MUC5B  MSMB  SCGB1A1  BPIFB1  SCGB3A1  TSPAN8  OMG  TMEM190 figure. c, t-SNE displaying the major epithelial clusters present in the full extent of the human respiratory tree. T1, type 1; T2, type 2. d, Pie charts depicting the cellular composition by anatomical region. e, Horizontal slice bar depicting the anatomical distribution of each cell type identified. f, Heat map depicting the average expression levels per cluster of the top differentially expressed markers in each cluster. g, Violin plots of selected markers identified by differential expression analysis comparing the two goblet subsets to each other. h, Violin plots of selected markers identified by differential expression analysis of ciliated 1 versus ciliated 2 clusters. i, Dot plot depicting gene expression levels and percentage of cells expressing genes associated with specific lung phenotypes according to the OMIM database. All the differential expression analyses in f-i were performed using the non-parametric two-sided Wilcoxon rank sum test in Seurat. All panels depict the number of cells and individuals described in b.
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Nature MediciNe was a minimum of six weeks before sample collection for all patients. Most patients had controlled asthma on inhaled corticosteroid withdrawal (asthma control questionnaire score < 1.5). The combined airway wall dataset reveals a cellular landscape dominated by epithelial cells, with minor contributions from endothelial, mesenchymal, and immune cells (Extended Data Fig. 6a,b and Supplementary Tables 4 and 5 ).
Clustering of the EPCAM + cells identified ten sub-clusters representing the six epithelial cell types observed in healthy airway wall (Fig. 1c) , as well as four additional cell states: mucous ciliated cells, activated basal cells, cycling cells, and serous cells from the submucosal glands (Fig. 3b) .
Activated basal cells closely resemble basal 1 cells, but also express proinflammatory genes such as POSTN (Fig. 3d) . Cycling GATA2  IL-2RG  CD96  IGHM  TNFRSF13B  CD79B  CD79A  CHCHD10  CD55  LIFR  HSPG2  MGP  IGFBP7  FBN1  COL6A2  CAV1  BGN Table with details of anatomical region, tissue source, donors, and cell numbers present in this figure. b, t-SNE displaying the major immune and mesenchymal clusters present in the full extent of the human respiratory tree. NK, natural killer. c, Pie charts depicting the cellular composition of immune cells by anatomical region. d, Pie charts depicting the cellular composition of stromal cells in lower airway biopsies and parenchyma tissue. e, Heat map depicting the average expression levels per cluster of the top differentially expressed markers in each cluster. f, Dot plot depicting gene expression levels and percentage of cells expressing genes associated with lung phenotypes according to the OMIM database. All the differential expression analyses in e and f were performed using the non-parametric two-sided Wilcoxon rank sum test in Seurat. All panels depict the number of cells and individuals described in a. 
Marker genes Table 5 . In box and whisker plots in c, all points are shown, and the box represents the second and third quartiles and median. All the differential expression analyses in d and g were performed using the non-parametric two-sided Wilcoxon rank sum test in Seurat. Panels b-d and g depict the number of cells and individuals described in a; e and f depict the number of individuals described in a.
Nature MediciNe basal cells are characterized by expression of canonical marker genes of proliferating cells (MKI67 and TOP2A) (Fig. 3d) , and this is the only cluster of airway epithelial cells expressing the squamous cell marker KRT13 (Extended Data Fig. 6 ). We observe mucous cell hyperplasia in asthma, with a marked increase in goblet cell numbers (Fig. 3c) , which are very rare in healthy airway wall biopsies (Fig. 1e) . Moreover, the goblet cell transcriptional phenotype is altered in asthma, with strong upregulation of proinflammatory and remodeling genes NOS2, CEACAM5, and CST1 (Fig. 3d) . In addition, we identified a strong increase in mucous ciliated cells, a novel cell state highly similar to ciliated cells, but co-expressing a number of mucous genes also observed in goblet cells, including MUC5AC and CEACAM5 and the ciliated genes FOXJ1 and PIFO (Fig. 3d and Extended Data Fig. 6 ).
To further dissect the inferred differentiation trajectories of epithelial cells in healthy and asthmatic airway walls, we performed pseudotime analysis 20 . This reveals a trajectory starting with basal cell subsets, bifurcating into either a secretory lineage (mainly club cells) and a ciliated lineage in healthy airway wall (Fig. 3e) . In asthma, the secretory lineage is a mix of club and goblet cells, while the mucous ciliated cell state is mapped to the ciliated differentiation trajectory (Fig. 3e,f) .
Next, we further analyzed the transcriptional profiles of the mucous ciliated and goblet cells. Fig. 7b ). In club cells, expression of Notch target genes 22, 23 does not differ between asthma-and healthy-derived cells. In contrast, in goblet cells, the Notch target gene signature is retained only in cells from healthy airway wall, and is lost in asthma. Interestingly, mucous ciliated cells also lack expression of Notch target genes in asthma (Extended Data Fig. 7 ). Hence, we postulate that mucous ciliated cells represent a transition cell state in the ciliated lineage-induced by IL-4/IL-13 signaling-leading to a mucous cell phenotype that contributes to mucous cell metaplasia in asthma 21 . Similar to goblet cells, mucous ciliated cells express key asthma genes such as CST1 25 and POSTN (Fig. 3d ), indicating that these cells can contribute to airway inflammation and remodeling.
Analysis of asthma genome-wide association study (GWAS) gene expression in our epithelial scRNA-seq data revealed a broad contribution of airway epithelial cell types to asthma susceptibility ( Fig. 3g) , with high expression of asthma GWAS genes in ciliated and mucous ciliated cells. This includes genes involved in ciliary function (DYNC2H1 and KIF3A), cell adhesion (ELK3, CDHR3 and PTPRT), and IL-5-induced mucus metaplasia (IL-5RA) 26 , further suggesting a direct link between mucous ciliated cells and T H 2 cells.
Remodeling of the stromal and immune compartments in asthmatic airways. Asthma is associated with chronic inflammation and remodeling of the airway wall 27 . Analysis of the immune and stromal cell populations (Fig. 4a ) in the bronchial biopsies by reveals the presence of B and T cells, neutrophils, macrophages, dendritic cells, mast cells, fibroblasts, smooth muscle cells, and endothelial cells ( Fig. 4b and Extended Data Fig. 8 ). We did not detect innate lymphoid, basophil, or eosinophil clusters (Extended Data Fig. 8 ). Analysis of bulk transcriptome data of matched airway wall biopsies before and after tissue dissociation identified very low expression levels of the eosinophil marker gene CLC, indicating that these cells are rare in the samples we analyzed (Extended Data Fig. 9 ).
Mast cell numbers were increased in asthma (Fig. 4c ). Mast cells in asthmatic airways lack chymase 1 expression (CMA1) and express high levels of tryptase genes (TPSB2, TPSAB1) and prostaglandin synthetase genes PTGS2 and HPGDS ( Fig. 4d and Extended Data Fig. 8d ). PTGS2 (cyclooxygenase-2), also known as inflammatory cyclooxygenase, converts the precursor arachidonic acid to prostaglandin endoperoxide H2 (PGH2 . Asthma GWAS genes show cell-type restricted expression (Fig. 4e) . When excluding the widely expressed HLA genes from the analysis, fibroblasts and T cells express the highest number of asthma GWAS genes (Fig. 4f) , which are also mostly upregulated in asthma (Fig. 4f) . GATA3 expression is restricted to T cells ( Fig. 4f ) and increased in patients with asthma ( Fig. 4f) . We detected upregulation of CD4 (but not CD8A) in the T cell cluster, suggesting an increase in T H 2 CD4
+ T cells (Fig. 4f ). Therefore, we investigated the CD4 + T cell compartment in airway wall biopsies in more detail.
Pathogenic effector T H 2 cells are enriched in asthmatic airways.
In line with the increased GATA3 and CD4 expression mentioned above, T H 2 cells are known to be key drivers of asthma 14, 32 . To assess the presence of T H 2 effector cells in the airways of patients with asthma ( Fig. 4f) , we single-cell sorted CD4 + T cells followed by indepth transcriptional phenotyping by SmartSeq2 profiling ( Fig. 5a and Methods). We analyzed cells from both peripheral blood and airway wall biopsies (Fig. 5a ) from a larger cohort of patients with asthma and healthy controls ( Fig. 5b and Supplementary Table 6 ). Unbiased clustering reveals six major populations of CD4 + T cells ( Fig. 5c and Extended Data Fig. 10 ) with no differences in their relative abundance between asthma and healthy airway wall (Fig. 5d ).
Comparative analysis of CD4 + T cells isolated from paired blood and lung samples allowed us to differentiate between tissue-resident and circulating T cells in an unbiased way ( Fig. 5e and Methods). We identified two CD4 + T cell subsets highly enriched in airway wall: the classical TRM CD4 + T cells, and a novel subset, which we named the tissue migratory CD4 + T cell (TMC) subset (Fig. 5e ). Naive/central memory (CM), effector memory (EM), and effector memory reexpressing CD45RA (EMRA) CD4 + T cells, as well as a mixed regulatory T cell (T reg )/T H 2 cluster, are either enriched in blood or present in both blood and airway wall biopsies (Fig. 5e ).
To better understand the two distinct lung airway-resident CD4 + T cell subsets, we performed differential expression analysis between TRM and TMC cells (Fig. 5f ). TRM cells lack S1PR1 and CCR7 expression. TRM cells in airway wall also expressed high levels of CXCR6 and ITGA1, chemokines (CCL4, CCL4L2, CCL5) and effector molecules (PRF1, GZMB, GZMA, GZMH) ( Fig. 5f and Extended Data Fig. 10 ), indicating they are in a primed state capable of direct effector function, as recently shown for TRMs from lung parenchyma 33 . TMC cells expressed the tissue egression markers S1PR1, CCR7, and SELL (CD62L) (Fig. 5f ) as well as several transcription factors highly expressed in circulating cells such as LEF1, SATB1, and KLF3. Small numbers of TMC cells were present in peripheral blood CD4 + T cells (Fig. 5e ), suggesting that these cells might have the potential to transit between lung, lymph, and blood. TOP2A  TYMS  RRM2  KIAA0101  MKI67  KLRB1  CD2  IL32  TRAC  CD3D  IGHG1  IGHG3  IGLC2  JCHAIN  MZB1  EREG  G0S2  S100A8  S100A9  FCN1  SDS  FAM26F  C1QC  C1QB  C1QA  CD1C  SPIB  FCER1A  LGALS2  IFI30  CCL18  VSIG4  FABP4  APOC1  MARCO  HPGDS  MS4A2  TPSB2  TPSAB1  CPA3  CXCL14  DCN  COL1A2  FBLN1  LUM  MYH11  RGS5  TAGLN  NDUFA4L2  ACTA2  SELE  CLDN5  VWF  ACKR1  AQP1  GJA4  CXCL12  SLC9A3R2 TTN  TNFRSF9  TIGIT  TBC1D4  STAM  SAT1  RTKN2  ICA1  F5  ENTPD1  CD27  IL2RA  PELI1  GBP2  CARD16  IL32  SELL  IKZF2  FOXP3  ARID5B  TMIGD2  MGAT4A  GPR65  ABCB1  IL23R  IL18RAP  IL17F  IL17A  THBS1  RYR2  PLN  PDLIM5  NENF  GPR35  CHDH  CACNA1D  C1orf162  BCAR3  IL9R  IL17RB  HPGDS  FFAR3  LIF  IL5  IL13  PPARG  RASGEF1B  ANXA1  GZMB  GZMA  AOAH  IFNG  CCL5  CCL4L2  CCL4 SASH3  HOPX  SYTL2  GZMB  GZMH  PRF1  GZMA  NKG7  F2R  PDCD1  AOAH  ALOX5AP  CCL4  CCL4L2  CCL5  CXCR6  ITGA1  JAML  ITGAE  ZEB2  PABPC1  EIF4B  HNRNPH1  EIF2S3_  WHSC1L1  SESN3  C9orf72  RASSF3  FAM65B  GCNT4  LDHB  CD55  SERINC5  SC5D  S1PR1  CCR7  SELL  KLF3  SATB1 
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Nature MediciNe relative proportions of the other T H subsets (Fig. 5h) . In addition to the signature cytokines IL4, IL5, and IL13 and the transcription factor GATA3 (Extended Data Fig. 10 Asthma is characterized by specific signaling networks. Asthma is characterized by remodeling of the airways, which depends on complex interactions between structural and inflammatory cells 14 , both via direct physical interactions and secreted proteins and small molecules. We used our recently developed receptor/ligand database and statistical inference framework CellPhoneDB 37 (www. cellphonedb.org) to identify potential cell-cell interactions in the airway wall, and define their changes in asthma. While most interactions are unchanged, some were specific to the diseased or healthy states (Supplementary Table 7) .
In healthy controls, the cell-cell interaction landscape of the airway wall was dominated by lung structural cells (mesenchymal and epithelial cell types) communicating with each other, and with both TRM and TMC CD4 + T cells (Fig. 6a,b , left panels). In the asthmatic airway wall, the number of predicted interactions between epithelial and mesenchymal cells was strongly reduced. Instead, the cell-cell communication landscape is dominated by T H 2 cells in asthma. T H 2 cells have increased predicted interactions with other immune cells, epithelial cells, and especially mesenchymal cells, both fibroblasts and smooth muscle cells (Fig. 6a,b, right panels) .
Analysis of the predicted cell-cell interactions between structural cells in healthy airway wall revealed a wealth of growth factor signalling pathways including the fibroblast growth factor (FGF), epidermal growth factor receptor (EGFR), insulin-like growth factor (IGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) pathways (Supplementary Table 7 ). Cell-cell interactions unique to asthma included T H 2-epithelial cell contacts (for example, KLRG1 and CD103/E-cadherin; integrin/tenascin-C). Epithelial expression of alarmins and cytokines, such as IL-33, TSLP, and TNFSF10/ TRAIL (Fig. 6d) , all of which are known to play a role in asthma [38] [39] [40] , might activate T H 2 cells expressing their receptors.
In addition to validating these well-known interactions, which for IL-33 and TSLP failed to reach statistical significance in our unbiased cell-cell interaction analysis, we identified novel epithelial-T H 2 cell interactions in asthma: the interactions between epithelial chemokines CXCL2, CXCL17, and their T H 2-expressed receptors (Fig. 6d) . Interestingly, mesenchymal cells share some of these interactions, such as expression of TNFSF10/TRAIL and MIF. Predicted mesenchymal-T H 2 cell interactions in asthma are CXCL12 and CCL11, expressed by fibroblasts and smooth muscle cells. Airway wall T H 2 cells in asthma express IL-5 and IL-13 (Fig. 5i) , with receptor expression by immune cells and epithelial cells, respectively, in line with the observed IL-13-driven gene signature in mucous ciliated and goblet cells in asthma (Extended Data Fig. 7) . In addition to these classical T H 2 cytokines, T H 2 cells express LTB for which basal epithelial cells express the receptor.
discussion
We describe the cellular landscape of human lung tissue at the single-cell level, charting differences in frequencies and molecular state of lung structural and inflammatory cells between upper and lower airways and parenchyma. We provide a first detailed molecular description of two separate tissue-resident subsets of CD4 + T cells in airway wall, one of which was hitherto unknown. We also conclusively show the presence of the recently identified 34-36 pathogenic effector T H 2 cells in the airway wall in asthma, as evidenced by the combined expression of IL5, IL13, HPGDS, PPARG, and IL17RB.
We identify a novel mucous ciliated cell state in asthmatic airway epithelium that contributes to mucous cell metaplasia. The gobletlike gene expression profile in FOXJ1 + cells with a full-blown ciliated cell transcriptional phenotype strongly indicates that this molecular state is induced in ciliated cells by type 2 cytokines. Mucous metaplasia of ciliated cells and goblet cell hyperplasia both contribute to the increase in mucin-producing cells in asthma.
These changes in airway epithelium in asthma differ from those in patients with chronic rhinosinusitis with polyps 24 . In this type 2 inflammatory upper airway disease, IL-4/IL-13-driven gene transcription was observed in basal cells, which were arrested in differentiation and increased in frequency 24 . In asthma, basal cell numbers are not strongly increased. Instead, we observe expression of the IL-4/IL-13-driven gene signature mainly in goblet and mucous ciliated cells (Extended Data Fig. 7 ). Hence, chronic type 2 inflammation has divergent effects on the epithelia of the upper versus the lower airways. In contrast, the changes in the eicosanoid pathway observed in chronic type 2 inflammation of the upper 24 and lower (Extended Data Fig. 8 ) airways are very similar, underscoring the presence of common cellular mechanisms between these two anatomical locations.
Finally, comprehensive analysis of the cell-cell interactions in airway wall in asthma identifies dominance of T H 2 cells interacting with structural and inflammatory cells. The extensive growth factor signaling between epithelial cells and mesenchymal cells observed in healthy airway wall is largely lost in asthmatic airway wall, at odds with a reactivation of the epithelial-mesenchymal trophic unit 41 . Instead, our data support a shift in cellular phenotypes in airway wall due to the local production of T H 2 cytokines in our patient cohort with mild to moderate childhood-onset asthma. This global view of the airway wall cellular landscape opens up new perspectives on lung biology and molecular mechanisms of asthma.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0468-5. 
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Methods
Patient recruitment and ethical approval. Bronchoscopy biopsy (10x and SmartSeq2 analysis).
Cohort inclusion criteria for all subjects were: age between 40 and 65 years old and a history of smoking <10 pack-years. For the patients with asthma, inclusion criteria were: age of onset of asthmatic symptoms ≤12 years old, documented history of asthma, use of inhaled corticosteroids with(out) β2-agonists due to respiratory symptoms, and a positive provocation test (that is, PC 20 methacholine (concentration of methacholine needed to produce a 20% fall in the forced expiratory volume in the first second (FEV 1 )) ≤ 8 mg ml −1 with 2 min protocol). For the non-asthmatic controls, the following criteria were essential for inclusion: absent history of asthma, no use of asthma-related medication, a negative provocation test (that is PC 20 methacholine >8 mg ml −1 , and adenosine 5′-monophosphate >320 mg ml −1 with 2 min protocol), no pulmonary obstruction (that is, FEV 1 /forced vital capacity (FVC) ≥ 70%) and absence of lung function impairment (that is FEV 1 ≥ 80% predicted).
Patients with asthma stopped inhaled corticosteroid use six weeks before all tests. All subjects were clinically characterized with pulmonary function and provocation tests, blood samples were drawn, and finally subjects underwent a bronchoscopy under sedation. If a subject developed upper respiratory symptoms, bronchoscopy was postponed for ≥6 weeks.
Fibreoptic bronchoscopy was performed using a standardized protocol during conscious sedation 42 . Six macroscopically adequate endobronchial biopsies were collected for this study, located between the third and sixth generation of the right lower and middle lobe. Extracted biopsies were processed directly thereafter, with a maximum of 1 h delay.
The medical ethics committee of the Groningen University Medical Center Groningen approved the study, and all subjects gave their written informed consent. Detailed patient information is given in Supplementary Table 3 .
Lung resection (Drop-seq analysis) . Fresh resected human lung tissue (parenchymal lung and distal airway specimens) was obtained via the CPC BioArchive at the Comprehensive Pneumology Center Munich (CPC-M). In total, we analyzed parenchymal tissue of uninvolved areas of tumor resection material from four patients. All participants gave written informed consent and the study was approved by the local ethics committee of the Ludwig-Maximilians University of Munich.
For transport from the surgeon to the laboratory, lung tissue samples were stored in ice-cold DMEM-F12 media and packed in thermo stable boxes. Tissue was processed with a maximum delay of 2 h after surgery. On delivery to the lab, tissue samples were assessed visually for qualification for the study.
Donor information is given in Supplementary Table 8 . Stopped: no details. Respiratory related information: chest X-ray shows reduced volume in right lung due to collapsed right lower lobe on admission. No history or record of respiratory issues. Time from death to cell lysis: 13 h 30 min.
Lung transplant tissue (10x analysis
Archived formalin-fixed paraffin-embedded lung blocks. Left-over frozen peripheral lung tissues from six current smokers and four non-smokers who underwent lung resection surgery. These subjects did not have a history of lung disease, apart from lung cancer for which the patients underwent surgery. Lung tissue samples were taken as distant from the tumor as possible. Thus, any possible effect of the tumor on the lung tissue was minimized. All samples were obtained according to national and local ethical guidelines and the research code of the University Medical Center Groningen. Sample information in given in Supplementary Table 9 .
Blood processing. Lithium heparin-anticoagulated whole blood (500 µl) was lysed using an ammonium chloride-potassium solution (155 mM ammonium chloride (NH 4 Cl), 10 mM potassium bicarbonate (KHCO 3 ), 0,1 mM EDTA). Cells were centrifuged for 5 min at 4 °C, 550g, after which the cell pellet was washed twice with PBS containing 1% BSA, followed by staining for cell surface markers.
Lung tissue processing. Bronchoscopy biopsy.
A single-cell solution was obtained by chopping the biopsies finely using a single edge razor blade. The chopped tissue was then put in a mixture of 1 mg ml −1 collagenase D and 0.1 mg ml −1 DNase I (Roche) in HBSS (Lonza). This was then placed at 37 °C for 1 h with gentle agitation. The single-cell suspension was forced through a 70 µm nylon cell strainer (Falcon). The suspension was centrifuged at 550g, 4 °C for 5 min and washed once with a PBS containing 1% BSA (Sigma-Aldrich). The single-cell suspensions used for 10x Genomics scRNA-seq analysis were cleared of red blood cells by using a red blood cell lysis buffer (eBioscience) followed by staining for cell surface markers.
Lung tissue resection. For each sample, 1.0-1.5 g of tissue was homogenized by mincing with scissors into smaller pieces (~0.5 mm 2 per piece). Before tissue digestion, lung homogenates were cleared from excessive blood by addition of 35 ml of ice-cold PBS, followed by gentle shaking and tissue collection using a 40 μm strainer. The bloody filtrate was discarded. The tissue was transferred into 8 ml of enzyme mix consisting of dispase (50 caseinolytic U ml ) for mild enzymatic digestion for 1 h at 37 °C while shaking. Enzyme activity was inhibited by adding 5 ml of PBS supplemented with 10% FCS. Dissociated cells in suspension were passed through a 70 μm strainer and centrifuged at 300g for 5 min at 4 °C. The cell pellet was resuspended in 3 ml of red blood cell lysis buffer and incubated at room temperature for 2 min to lyse remaining red blood cells. After incubation, 10 ml of PBS supplemented with 10% FCS was added to the suspension and the mix was centrifuged at 300g for 5 min at 4 °C. The cells were taken up in 1 ml of PBS supplemented with 10% FCS, counted using a Neubauer chamber, and critically assessed for single-cell separation. Dead cells were counted to calculate the overall cell viability, which needed to be above 85% to continue with Dropseq. Two-hundred and fifty thousand cells were aliquoted in 2.5 ml of PBS supplemented with 0.04% of bovine serum albumin and loaded for Drop-seq at a final concentration of 100 cells μl
Rejected lung transplant. For each sample, 1-2 g of tissue was divided in 5 smaller pieces then transferred to 5 ml eppendorfs containing 1.5 ml 0.5 mg ml −1 collagenase D and 0.1 mg ml −1 DNase I (Sigma) in RPMI. Samples were then finely minced using scissors. Minced tissue was then transferred to a Petri dish and extra digestion medium added to completely cover the tissue. Samples were incubated 30 min at 37 °C. Cells were then passed up and down through a 16-gauge needle 10 times. Samples were incubated for an additional 15 min at 37 °C. Cells were filtered a 70 μm filter, then spun down for 6 min 1,400 r.p.m. One milliliter of red blood cell lysis (eBioscience) was added to the pellet during 5 min. Cells were resuspended in RPMI + 10%FCS and counted. Dead cells were removed using the Dead Cell Removal Kit (Miltenyi Biotec). In brief, cells were incubated with anti-annexin V beads for 15 min. The cell suspension was then passed through a magnetic column and dead annexin V + cells remained in the column, while live cells were collected. Viability was then estimated via trypan blue. More than 99% of cells were viable.
Flow cytometry. Blood leukocytes were stained with CD4 APC-Cy7, CD3 PerCP Cy5.5, CD8 APC, and CD45RA-PE (eBioscience) for 30 min at 4 °C and washed twice with PBS containing 1% BSA. Propidium iodide was added 5 min before sorting.
Airway wall biopsy single-cell suspensions were stained for 30 min at 4 °C with CD3 PerCP Cy5.5, CD45 BB515, CD4 APC-Cy7 (BD), and CD8 PE and washed twice with PBS containing 1% BSA. Propidium iodide was added 5 min before sorting.
Cell sorting. Lymphocytes were selected in the FCS/SSC plot. These were then selected on single, live cells for blood or single, live, CD45
+ for lung. The sorted cells were positive for CD3 and CD4 as shown in Fig. 5a . All cells were sorted in a MoFlo Astrios (Beckman Coulter) using Summit Software (Beckman Coulter).
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Immunohistochemical staining. Human lung tissue containing large airways were collected from archival formalin-fixed paraffin-embedded blocks (n = 10, 6 smokers and 4 non-smokers). Serial sections (∼4 µm) were cut for immunohistochemistry (IHC) and immunofluorescent (IF) staining.
Serial sections from formalin-fixed paraffin-embedded lung tissue were stained for using standard protocols, with antibodies specified in the figures. Briefly, serial sections were deparaffinized in xylene, rehydrated, and immersed in 10 mM sodium citrate buffer (pH 6.0). Antigen retrieval was performed by boiling the sections in a pressure cooker at 120 °C for 20 min.
IHC and IF staining was performed as described previously 43, 42 . For the IHC staining cells were stained with a primary antibody (see below for antibody details) and visualized with diaminobenzidine (DAB, Sigma) solution. For the IF staining, cells were stained with primary antibody. Secondary antibodies conjugated to fluorophores (donkey anti-rabbit-488, donkey anti-mouse-555) were used at a dilution of 1:100. DAPI, dissolved in Dako Fluorescence Mounting Medium (Dako S3023) at a dilution of 1:1,000, was used as a nuclear stain.
Fluorescence in situ hybridization. Fluorescent in situ hybridization was performed with the ACD Biotechne RNAscope kit according to the manufacturers' manual. In short, formalin-fixed paraffin-embedded lung biopsies were cut at 4 µm. Sections were deparaffinized and boiled in the microwave in the Target Retrieval buffer. Protease activity was blocked and the slides were incubated with FOXJ1 (430921-c1) and MUC5AC (312891-c3) probes. The fluorochromes Cy5 (FoxJ1) and Cy3 (MUC5AC) were bound to the probes, the nuclei were counterstained with DAPI and the slides were covered with a coverslip and imaged under the Leica SP8 Confocal Laser Scan Microscope.
Chromium 10x Genomics library and sequencing. Airway biopsy. Single-cell suspensions were manually counted using a haemocytometer and concentration adjusted to a minimum of 300 cells μl −1 . Cells were loaded according to standard protocol of the Chromium single-cell 3′ kit to capture between 2,000 and 5,000 cells per chip position. All the following steps were performed according to the standard protocol. Initially, we used one lane of an Illumina Hiseq 4000 per 10x Genomics chip position. Additional sequencing was performed to obtain coverage of at least mean coverage of 100,000 reads per cell.
Lung transplant. Single-cell suspensions were manually counted using a haemocytometer and concentration adjusted to 1,000 cells μl −1 . Cells were loaded according to standard protocol of the Chromium single-cell 3′ kit to capture between 2,000 and 5,000 cells per chip position. All the following steps were performed according to the standard manufacturer protocol. Initially, we used one lane of an Illumina Hiseq 4000 per 10x Genomics chip position. Additional sequencing was performed to obtain coverage of at least mean coverage of 100,000 reads per cell.
Antibody list.
A full antibody list is given in Supplementary Table 10 .
SmartSeq 2 library preparation and sequencing. Library preparation was performed with minor modifications from the published SmartSeq2 protocol 44 . In short, single cells were flow sorted onto individual wells of 96 or 384 wells containing 4 μl (96 wells) or 1 μl (384 wells) of lysis buffer (0.3% triton plus DNTPs and OligoDT). After sorting, plates were frozen and stored at −80 °C until further processing. PCR with reverse transcription (25 cycles) and Nextera library preparation performed as described in ref. 44 .
Drop-seq library preparation and sequencing. Drop-seq experiments were performed largely as described previously 2 with few adaptations during the single-cell library preparation. Briefly, using a microfluidic polydimethylsiloxane device (Nanoshift), single cells (100 µl −1 ) from the lung cell suspension were co-encapsulated in droplets with barcoded beads (120 µl −1 , purchased from ChemGenes) at rates of 4,000 µl h −1 . Droplet emulsions were collected for 15 min each before droplet breakage by perfluorooctanol (Sigma-Aldrich). After breakage, beads were collected and the hybridized mRNA transcripts reverse transcribed (Maxima RT, Thermo Fisher). Unused primers were removed by the addition of exonuclease I (New England Biolabs), following which beads were washed, counted, and aliquoted for pre-amplification (2,000 beads per reaction, equals ~100 cells per reaction) with 12 PCR cycles (primers, chemistry, and cycle conditions identical to those previously described). PCR products were pooled and purified twice by 0.6x clean-up beads (CleanNA). Before tagmentation, cDNA samples were loaded on a DNA High Sensitivity Chip on the 2100 Bioanalyzer (Agilent) to ensure transcript integrity, purity, and amount. For each sample, 1 ng of pre-amplified cDNA from an estimated 1,000 cells was tagmented by Nextera XT (Illumina) with a custom P5 primer (Integrated DNA Technologies). Single-cell libraries were sequenced in a 100 bp pairedend run on the Illumina HiSeq4000 using 0.2 nM denatured sample and 5% PhiX spike-in. For priming of read 1, 0.5 µM Read1CustSeqB (primer sequence: GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC) was used.
Bulk transcriptome. Biopsies were fresh frozen in liquid nitrogen and stored at −80 °C. RNA was extracted after a few weeks using a combination of Trizol and the RNeasy MinElute Clean Up kit from Qiagen. RNA was prepared from sequencing using the TruSeq RNA Library Prep Kit v2. Samples were then sequenced inn a Hiseq 4000.
Single-cell RNA sequencing data alignment. For SmartSeq2 raw sequencing data, paired-end reads were mapped to the human genome (GRCh38) using GSNAP with default parameters 45 . Then, uniquely mapped reads were counted using htseqcount (http://www-huber.embl.de/users/anders/HTSeq/). Low-quality cells were filtered out using the outlier detection algorithm in R Scater package based on a cut-off of 2 × median absolute deviation.
10x Genomics raw sequencing data were processed using CellRanger software version 2.0.2 and the 10x human genome GRCh38 1.2.0 release as the reference.
The Drop-seq core computational pipeline was used for processing next generation sequencing reads of the Drop-seq scRNA-seq data, as previously described 2 . Briefly, STAR (version 2.5.2a) was used for mapping 46 . Reads were aligned to the human reference genome hg19 (provided by Drop-seq group, GSE63269).
Bulk transcriptome computational analysis. The bulk samples were aligned using STAR 2.5.1b, using the STAR index from the GRCh38 reference that was used when mapping 10x data, and quantified using HTSeq. The data were then processed using the Seurat-inspired workflow within Scanpy, adding a number of 'pseudo-bulks' obtained by taking 10x data from donors matching the bulk samples and summing expression across all cells.
Data quality control.
General strategy for 10x datasets. Optimal tissue dissociation conditions are cell-type dependent, resulting in a certain degree of cell lysis when working with a mixed tissue sample. This results in substantial background levels of ambient RNA in the single-cell suspension that vary with cell-type composition, so we applied SoupX for background correction (see below). We analyzed each donor sample separately and excluded cells with a number of genes higher than the median + 2 s.d. for that donor. We further excluded cell with high number of unique molecular identifiers (UMIs) and high percentage of mitochondrial reads (see below).
In parallel, we used scrublet (see below) to infer the number of the doublets in the dataset before applying the filters previously described and excluded any remaining cells predicted to be doublets that were still present in the dataset. We normalized and scaled our data (see below), performed clustering (see below), and identified and subset the data into epithelial and non-epithelial cell groups (as shown in Extended Data Figs. 1 and 5 ). After separation between epithelial and non-epithelial, we clustered the cells and performed curated doublet removal (see below) based on known lineage restricted markers.
General strategy for Drop-seq data. We normalized and scaled the data, then performed filtering based on the number of genes and percentage of mitochondrial reads.
General strategy SmartSeq2 data. We normalized and scaled the data, then performed filtering based on the number of genes and percentage of mitochondrial reads. To avoid potential batch effects from the lung digestion protocol, we corrected the gene expression of the CD4 SmartSeq2 dataset using a small subset of genes, the expression of which has been recently shown to be highly responsive to enzymatic digestion 47 : FOS, ZFP36, JUN, FOSB, HSPA1A, JUNB, EGR1, UBC. Ambient RNA correction (SoupX). Different batches can be affected by different levels of ambient RNA. To take this into account, we used the recently developed SoupX method 48 . Briefly, ambient RNA expression is estimated from the empty droplet pool (10 UMI or less). Expression of these genes in each cell is then calculated and compared with their proportion in the ambient RNA profile. Transcripts with a bimodal profile (that is, that characterize specific groups of cells but are also highly abundant in empty droplets) are then grouped based on their function. The contamination fraction derived from the expression of these genes is then used to calculate the fraction of each droplet's expression corresponding to the actual cell. Finally, this fraction and the ambient profiles are subtracted from the real expression values.
UMI and number of genes filtering. 10x data (after SoupX correction). nUMI: minimum 1000/maximum 60000. percent.mito, minimum 0/maximum = 3%.
SmartSeq2 data. nGene: minimum 1000/maximum 4000. percent.mito, minimum 0/maximum = 15%.
Drop-seq data. nGene: minimum 200/maximum 4000. percent.mito, minimum 0/ maximum = 20%.
Scrublet. We used Scrublet 49 for unbiased computational doublet inference. Doublets were identified in each 10x sample individually using Scrublet, setting the expected doublet rate to 0.03 and keeping all other parameters at their default values. Cells were excluded when they had a score higher than 0.1 for upper and lower airway samples or higher than 0.05 for parenchyma samples. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Data collection
No specific code was used for data collection. The data depicted in this manuscript was generated by us.
Data analysis
Analysis performed in R version 3.4. Seurat v3. Monocle 2. FlowJo 10, Summit Software, CellRanger v 2.0.2, STAR v 2.5.2a, GSNAP, htseqcount, Scrublet, MatchSCore, Cytoscape v 3.5.1, CellPhoneDB.
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Sample size
The exact number of donors used per figure is informed in each figure. IN the whole manuscript, they are: 11 healthy bronchoscopic biopsies (fresh) 9 asthma bronchoscopic biopsiesn(fresh) 6 lung transplant donors (fresh) 4 lung resection tissues (fresh) 10 lung resection samples (frozen and parafin blocks)
No sample size calculation performed.
Data exclusions Several single cells were excluded from analysis. QC criteria is present in the methods and below:
UMI and number of genes filtering 10x data (After SoupX correction): nUMI: minimum 1000/ maximum 60000. percent.mito, minimum 0 / maximum= 3% SmartSeq2 data: nGene : minimum 1000 / maximum 4000. percent.mito, minimum 0 / maximum= 15% Dropseq data: nGene: minimum 200/ maximum 4000. percent.mito, minimum 0 / maximum= 20% Scrublet We used Scrublet (Wolock et al, BioRxiv, https://doi.org/10.1101/357368) for unbiased computational doublet inference. Doublets were identified in each 10X sample individually using scrublet, setting the expected doublet rate to 0.03 and keeping all other parameters at their default values. Cells were excluded when they had a score higher than 0.1 for upper and lower airway samples or higher than 0.05 for parenchyma samples.
Curated doublet removal
In addition to the general QC described above, we combined literature knowledge about cell lineages with computational clustering to identify clusters enriched in potential doublets. The strategy for each dataset is described below:
Lung atlas epithelial dataset ( Figure 1 and associated Extended data Figures): We removed cells with expression level higher than 0.5 for any of the following markers: PTPRC (immune),FCER1G (immune), PDGFRA (fibroblast) or PECAM1 (endothelial).
Lung atlas non-epithelial dataset ( Figure 2 and associated Extended data Figures): We removed cells with expression level higher than 0.5 for any of the following markers: EPCAM (epithelial),KRT5 (basal), "FOXJ1"(ciliated) or MUC5AC (secretory). We then performed first clustering round (7 PCs, resolution 2) and excluded clusters that expressed combinations of the following lineage specific markers: MARCO(macrophage), CCL21 (lymphatic endothelial), TPSB2 (mast cell) or CD3D(T cell). We performed a second clustering round and exclude a cluster formed by cells from one donor that had low expression TPSB2, while lacking markers for all other immune lineages.
Asthma biopsy epithelial cells ( Figure 3 and associated Extended data Figures): due to the smaller number of cells, in addition to the general QC metrics, we only performed cluster-based doublet exclusion, without cell filtering. We performed one round of clustering and removed one clusters with high expression of PECAM1 (endothelial marker).
Asthma biopsy non-epithelial cells (Figure 4 and associated Extended data Figures): in addition to the general QC metrics, we performed three rounds of clustering where we excluded clusters with high levels of EPCAM or KRT5 expressed in much higher levels than immune lineage markers.
Replication
We have replicated the existence of mucous-cliaiated cells using Fluorescence in situ hybridization in one asthmatic patient. Further analysis of larger cohorts are recomended as future work. Other findings not directly replicated due to the broad scope of the work.
Randomization Not applicable. Samples were segregated based on anatomical location or clinical status (for asthma).
